NCT01364415View on ClinicalTrials.gov

Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs)

PHASE1CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions
Neuroendocrine Tumors
Interventions
DRUG

Pasireotide LAR

Trial Locations (4)

33612

H. Lee Moffitt Cancer Center & Research Institute SC-1, Tampa

90048

Cedars Sinai Medical Center Cedars Sinai 4, Los Angeles

02215

Dana Farber Cancer Institute SC-6, Boston

77030-4009

University of Texas/MD Anderson Cancer Center UT MD Anderson Cancer Ctr, Houston

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY